One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus
Publication type: Journal Article
Publication date: 2015-10-01
scimago Q2
wos Q2
SJR: 1.279
CiteScore: 7.1
Impact factor: 3.8
ISSN: 15216616, 15217035
PubMed ID:
26073226
Immunology
Immunology and Allergy
Abstract
Inflammation associated with obesity is involved in the development of insulin resistance. We hypothesized that anti-inflammatory treatment with the Interleukin-1 receptor antagonist anakinra would improve insulin sensitivity. In an open label proof-of-concept study, we included overweight patients diagnosed with type 1 diabetes with an HbA1c level over 7.5%. Selecting insulin resistant patients with longstanding type 1 diabetes allowed us to study the effects of anakinra on insulin sensitivity. Patients were treated with 100mg anakinra daily for one week. Insulin sensitivity, insulin need and blood glucose profiles were measured before, after one week and after four weeks of follow-up. Fourteen patients completed the study. One week of anakinra treatment led to an improvement of insulin sensitivity, an effect that was sustained for four weeks. Similarly, glucose profiles, HbA1c levels and insulin needs improved. In conclusion, one week of treatment with anakinra improves insulin sensitivity in patients with type 1 diabetes.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
PLoS ONE
2 publications, 3.33%
|
|
|
Trends in Endocrinology and Metabolism
2 publications, 3.33%
|
|
|
Trends in Molecular Medicine
2 publications, 3.33%
|
|
|
Nauchno-Prakticheskaya Revmatologiya
2 publications, 3.33%
|
|
|
Diabetes/Metabolism Research and Reviews
2 publications, 3.33%
|
|
|
Journal of Immunology
1 publication, 1.67%
|
|
|
Journal of Molecular Medicine
1 publication, 1.67%
|
|
|
Current Opinion in Neurology
1 publication, 1.67%
|
|
|
Medicine (United States)
1 publication, 1.67%
|
|
|
World Journal of Diabetes
1 publication, 1.67%
|
|
|
Diabetology
1 publication, 1.67%
|
|
|
Molecules
1 publication, 1.67%
|
|
|
Frontiers in Cardiovascular Medicine
1 publication, 1.67%
|
|
|
Frontiers in Immunology
1 publication, 1.67%
|
|
|
Reviews in Endocrine and Metabolic Disorders
1 publication, 1.67%
|
|
|
Diabetologia
1 publication, 1.67%
|
|
|
Nature Reviews Drug Discovery
1 publication, 1.67%
|
|
|
Current Diabetes Reports
1 publication, 1.67%
|
|
|
Clinical Reviews in Allergy and Immunology
1 publication, 1.67%
|
|
|
Journal of Endocrinological Investigation
1 publication, 1.67%
|
|
|
Archives of Dermatological Research
1 publication, 1.67%
|
|
|
Scientific Reports
1 publication, 1.67%
|
|
|
Immunity
1 publication, 1.67%
|
|
|
Diabetes and Metabolism
1 publication, 1.67%
|
|
|
Clinical Immunology
1 publication, 1.67%
|
|
|
JACC: Basic to Translational Science
1 publication, 1.67%
|
|
|
Medecine des Maladies Metaboliques
1 publication, 1.67%
|
|
|
Journal of Pediatrics
1 publication, 1.67%
|
|
|
Immunobiology
1 publication, 1.67%
|
|
|
1
2
|
Publishers
|
2
4
6
8
10
12
14
16
18
20
|
|
|
Elsevier
19 publications, 31.67%
|
|
|
Springer Nature
11 publications, 18.33%
|
|
|
Wiley
7 publications, 11.67%
|
|
|
MDPI
4 publications, 6.67%
|
|
|
Taylor & Francis
3 publications, 5%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 3.33%
|
|
|
Frontiers Media S.A.
2 publications, 3.33%
|
|
|
Public Library of Science (PLoS)
2 publications, 3.33%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 3.33%
|
|
|
Hindawi Limited
2 publications, 3.33%
|
|
|
Mediar Press
2 publications, 3.33%
|
|
|
The American Association of Immunologists
1 publication, 1.67%
|
|
|
Baishideng Publishing Group
1 publication, 1.67%
|
|
|
Radcliffe Media Media Ltd
1 publication, 1.67%
|
|
|
Touch Medical Media LTD.
1 publication, 1.67%
|
|
|
2
4
6
8
10
12
14
16
18
20
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
61
Total citations:
61
Citations from 2024:
11
(18.33%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Van Asseldonk E. J. P. et al. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus // Clinical Immunology. 2015. Vol. 160. No. 2. pp. 155-162.
GOST all authors (up to 50)
Copy
Van Asseldonk E. J. P., Van Poppel P. C. M., Ballak D. B., Stienstra R., Netea M. G., Tack C. J. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus // Clinical Immunology. 2015. Vol. 160. No. 2. pp. 155-162.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.clim.2015.06.003
UR - https://doi.org/10.1016/j.clim.2015.06.003
TI - One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus
T2 - Clinical Immunology
AU - Van Asseldonk, Edwin J P
AU - Van Poppel, Pleun C M
AU - Ballak, Dov B.
AU - Stienstra, Rinke
AU - Netea, Mihai G.
AU - Tack, Cees J.
PY - 2015
DA - 2015/10/01
PB - Elsevier
SP - 155-162
IS - 2
VL - 160
PMID - 26073226
SN - 1521-6616
SN - 1521-7035
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2015_Van Asseldonk,
author = {Edwin J P Van Asseldonk and Pleun C M Van Poppel and Dov B. Ballak and Rinke Stienstra and Mihai G. Netea and Cees J. Tack},
title = {One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus},
journal = {Clinical Immunology},
year = {2015},
volume = {160},
publisher = {Elsevier},
month = {oct},
url = {https://doi.org/10.1016/j.clim.2015.06.003},
number = {2},
pages = {155--162},
doi = {10.1016/j.clim.2015.06.003}
}
Cite this
MLA
Copy
Van Asseldonk, Edwin J. P., et al. “One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus.” Clinical Immunology, vol. 160, no. 2, Oct. 2015, pp. 155-162. https://doi.org/10.1016/j.clim.2015.06.003.